Incyte Corporation (INCY)
Health Care2 articles
Price chart
Why is INCY moving today?
+1.8%INCY is +1.8% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 4 hours ago
Incyte Corporation (INCY) overview
Incyte is a biopharmaceutical company focused on oncology.
INCY is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Incyte Corporation trades on the NasdaqGS under the ticker symbol INCY. The most recent market data puts the share price at about $126.93. That is up 1.83% on the session. At that price the company is worth roughly $25.73B.
Over the past 52 weeks, INCY has traded between $81.09 and $132.60. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 16.2. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns.
Key statistics
Source: Yahoo Finance - quote as of 4 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch INCY
INCY is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each INCY story as it breaks, and tags it bullish, bearish or neutral.
What moves INCY
- Earnings. INCY reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from INCY.
- Sector news. Health Care stocks often move together, so a rival's news can move INCY too.
Market Mood
Latest INCY news
Incyte Stock (INCY) Surges; Analysts Report Positive Developments
Incyte (INCY) stock saw a significant increase today following positive analyst reports concerning the company's latest clinical trials. The reports indicated a 20% improvement in treatment efficacy compared to previous results. Additionally, the overall trading volume for Incyte rose by 35% compared to the last week. This surge in stock price and volume indicates positive sentiment around the company's prospects and potentially foreshadows future growth in investor interest.
Read More: Incyte Stock (INCY) Surges; Analysts Report Positive Developments
Incyte (INCY) Stock Rating Reaffirmed Following Medicaid Settlement
H.C. Wainwright has reiterated its rating for Incyte (INCY) following a settlement related to Medicaid. The specifics of the settlement are undisclosed, but the firm maintains confidence in the company's prospects. The continuity in the rating suggests stable expectations for the stock moving forward. Market reactions will be monitored as additional details may impact trading volumes and investment sentiment.
Read More: Incyte (INCY) Stock Rating Reaffirmed Following Medicaid SettlementMore Health Care stocks
Frequently asked questions
Is Incyte Corporation in the S&P 500?
Yes. Incyte Corporation trades as INCY and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is INCY in?
INCY sits in the Health Care sector of the S&P 500.
Where can I find the latest INCY news?
Right here. This page collects recent INCY news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Incyte Corporation's stock price?
INCY last traded at about $126.93. Prices move all through the session, so this is the latest quote rather than a live one.
What is Incyte Corporation's market cap?
INCY is worth roughly $25.73B. Market cap is the share price times the number of shares outstanding.
What is INCY's P/E ratio?
INCY trades at a trailing P/E ratio of about 16.2. The ratio compares the share price with earnings per share over the past year.